Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy.

Amaddeo G, Nguyen CT, Maillé P, Mulé S, Luciani A, Machou C, Rodrigues A, Regnault H, Mallat A, Laurent A, Lafdil F, Hézode C, Pawlotsky JM, Calderaro J.

Liver Int. 2019 Aug 24. doi: 10.1111/liv.14226. [Epub ahead of print]

PMID:
31444947
2.

Adeno-associated virus in the liver: natural history and consequences in tumour development.

La Bella T, Imbeaud S, Peneau C, Mami I, Datta S, Bayard Q, Caruso S, Hirsch TZ, Calderaro J, Morcrette G, Guettier C, Paradis V, Amaddeo G, Laurent A, Possenti L, Chiche L, Bioulac-Sage P, Blanc JF, Letouze E, Nault JC, Zucman-Rossi J.

Gut. 2019 Aug 2. pii: gutjnl-2019-318281. doi: 10.1136/gutjnl-2019-318281. [Epub ahead of print]

PMID:
31375600
3.

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.

Iavarone M, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, Amaddeo G, Manini MA, López MF, Anders M, Pinter M, Rodríguez MJB, Cristóbal MR, Soteras GA, Piñero F, Villadsen GE, Weinmann A, Crespo G, Mazzaferro V, Regnault H, Giorgio M, González-Diéguez ML, Donato MF, Varela M, Wörns MA, Bruix J, Lampertico P, Reig M.

Am J Transplant. 2019 Jul 31. doi: 10.1111/ajt.15551. [Epub ahead of print]

PMID:
31365177
4.

ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma.

Calderaro J, Meunier L, Nguyen CT, Boubaya M, Caruso S, Luciani A, Amaddeo G, Regnault H, Nault JC, Cohen J, Oberti F, Michalak S, Bouattour M, Vilgrain V, Pageaux GP, Ramos J, Barget N, Guiu B, Paradis V, Aubé C, Laurent A, Pawlotsky JM, Ganne-Carrié N, Zucman-Rossi J, Seror O, Ziol M.

Clin Cancer Res. 2019 Oct 1;25(19):5859-5865. doi: 10.1158/1078-0432.CCR-19-0859. Epub 2019 Jul 29.

PMID:
31358545
5.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.

Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman-Rossi J.

Hepatology. 2019 Jun 17. doi: 10.1002/hep.30811. [Epub ahead of print]

PMID:
31206197
6.

Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.

Gougelet A, Sartor C, Senni N, Calderaro J, Fartoux L, Lequoy M, Wendum D, Talbot JN, Prignon A, Chalaye J, Imbeaud S, Zucman-Rossi J, Tordjmann T, Godard C, Bossard P, Rosmorduc O, Amaddeo G, Colnot S.

Gastroenterology. 2019 Sep;157(3):807-822. doi: 10.1053/j.gastro.2019.05.069. Epub 2019 Jun 10.

PMID:
31194980
7.

Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.

Reizine E, Ronot M, Pigneur F, Purcell Y, Mulé S, Dioguardi Burgio M, Calderaro J, Amaddeo G, Laurent A, Vilgrain V, Luciani A.

Eur Radiol. 2019 Jul;29(7):3791-3801. doi: 10.1007/s00330-019-06150-7. Epub 2019 Apr 1.

PMID:
30937584
8.

Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress.

Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, Bacq D, Meyer V, La Bella T, Debaillon-Vesque A, Bioulac-Sage P, Seror O, Blanc JF, Calderaro J, Deleuze JF, Imbeaud S, Zucman-Rossi J, Letouzé E.

Nat Commun. 2018 Dec 7;9(1):5235. doi: 10.1038/s41467-018-07552-9.

9.

Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.

Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, Luciani A, Amaddeo G, Derman J, Charpy C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C.

J Hepatol. 2019 Jan;70(1):58-65. doi: 10.1016/j.jhep.2018.09.003. Epub 2018 Sep 11.

PMID:
30213589
10.

Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.

Reizine E, Amaddeo G, Pigneur F, Baranes L, Legou F, Mulé S, Zegai B, Roche V, Laurent A, Rahmouni A, Calderaro J, Luciani A.

Eur Radiol. 2018 Oct;28(10):4243-4253. doi: 10.1007/s00330-018-5438-7. Epub 2018 May 2.

PMID:
29721686
11.

Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.

Chalaye J, Costentin CE, Luciani A, Amaddeo G, Ganne-Carrié N, Baranes L, Allaire M, Calderaro J, Azoulay D, Nahon P, Seror O, Mallat A, Soussan M, Duvoux C, Itti E, Nault JC.

J Hepatol. 2018 Aug;69(2):336-344. doi: 10.1016/j.jhep.2018.02.018. Epub 2018 Mar 6.

PMID:
29518452
12.

Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.

Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-Rossi J, Barget N, Seror O, Ganne-Carrié N, Paradis V, Calderaro J.

Hepatology. 2018 Jul;68(1):103-112. doi: 10.1002/hep.29762. Epub 2018 May 9.

PMID:
29281854
13.

Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.

Costentin CE, Decaens T, Laurent A, Nault JC, Paule B, Letoublon C, Luciani A, Calderaro J, Adam R, Bricault I, Amaddeo G, Cherqui D, Mallat A, Samuel D, Duvoux C, Ganne-Carrié N, Roudot-Thoraval F, Vibert E.

Liver Int. 2017 Dec;37(12):1869-1876. doi: 10.1111/liv.13491. Epub 2017 Jul 13.

PMID:
28609020
14.

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.

Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, Nault JC, Zucman-Rossi J.

J Hepatol. 2017 Oct;67(4):727-738. doi: 10.1016/j.jhep.2017.05.014. Epub 2017 May 19.

PMID:
28532995
15.

Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models.

Costentin CE, Amaddeo G, Decaens T, Boudjema K, Bachellier P, Muscari F, Salamé E, Bernard PH, Francoz C, Dharancy S, Vanlemmens C, Radenne S, Dumortier J, Hilleret MN, Chazouillères O, Pageaux GP, Calderaro J, Laurent A, Roudot-Thoraval F, Duvoux C; Liver Transplantation French Study Group.

Liver Int. 2017 May;37(5):717-726. doi: 10.1111/liv.13388. Epub 2017 Mar 24.

PMID:
28199760
16.

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.

Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay D, Lafdil F, Pawlotsky JM.

Hepatology. 2016 Dec;64(6):2038-2046. doi: 10.1002/hep.28710. Epub 2016 Aug 9.

PMID:
27359084
17.

Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.

Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C; European Liver and Intestine Association (ELITA).

J Hepatol. 2016 Sep;65(3):524-31. doi: 10.1016/j.jhep.2016.05.010. Epub 2016 May 17.

PMID:
27212241
18.

Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas.

Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman-Rossi J.

Gut. 2015 May;64(5):820-9. doi: 10.1136/gutjnl-2013-306228. Epub 2014 Jun 9.

19.

BRAF V600E mutations in bile duct adenomas.

Pujals A, Amaddeo G, Castain C, Bioulac-Sage P, Compagnon P, Zucman-Rossi J, Azoulay D, Leroy K, Zafrani ES, Calderaro J.

Hepatology. 2015 Jan;61(1):403-5. doi: 10.1002/hep.27133. Epub 2014 May 19. No abstract available.

PMID:
24634053
20.

Next-generation sequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors.

Amaddeo G, Guichard C, Imbeaud S, Zucman-Rossi J.

Oncoimmunology. 2012 Dec 1;1(9):1612-1613.

21.

When activated oncogene meets immunity: a fight to prevent liver tumor initiation.

Nault JC, Amaddeo G, Zucman-Rossi J.

Hepatology. 2012 Jul;56(1):387-9. No abstract available.

PMID:
22876365
22.

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.

Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J.

Nat Genet. 2012 May 6;44(6):694-8. doi: 10.1038/ng.2256.

23.

Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels.

Pollicino T, Amaddeo G, Restuccia A, Raffa G, Alibrandi A, Cutroneo G, Favaloro A, Maimone S, Squadrito G, Raimondo G.

Hepatology. 2012 Aug;56(2):434-43. doi: 10.1002/hep.25592. Epub 2012 Jul 13.

PMID:
22271491
24.

Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis.

Di Marco V, Calvaruso V, Iacò A, Bronte F, Biasi L, Prestini K, Sacchi P, Amaddeo G, Squadrito G, Bruno R, Puoti M, Craxì A.

Gut. 2011 Jul;60(7):1023. doi: 10.1136/gut.2010.228478. Epub 2010 Dec 9. No abstract available.

PMID:
21148573
25.

An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers.

Maimone S, Calvaruso V, Pleguezuelo M, Squadrito G, Amaddeo G, Jacobs M, Khanna P, Raimondo G, Dusheiko G.

J Viral Hepat. 2009 Nov;16(11):769-74. doi: 10.1111/j.1365-2893.2009.01120.x. Epub 2009 Aug 26.

PMID:
19709363

Supplemental Content

Loading ...
Support Center